Globus Medical Stock Forecast, Price & News

Globus Medical (NYSE:GMED) Frequently Asked Questions

Is Globus Medical a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Globus Medical stock.
View analyst ratings for Globus Medical or view top-rated stocks.

How has Globus Medical's stock been impacted by COVID-19 (Coronavirus)?

Globus Medical's stock was trading at $38.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GMED shares have increased by 65.8% and is now trading at $63.09.
View which stocks have been most impacted by COVID-19.

Are investors shorting Globus Medical?

Globus Medical saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 782,200 shares, a drop of 31.4% from the October 31st total of 1,140,000 shares. Based on an average trading volume of 463,800 shares, the days-to-cover ratio is currently 1.7 days.
View Globus Medical's Short Interest.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for Globus Medical.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) released its quarterly earnings data on Thursday, November, 4th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.45 by $0.05. The medical device company had revenue of $229.72 million for the quarter, compared to analyst estimates of $228.28 million. Globus Medical had a net margin of 19.87% and a trailing twelve-month return on equity of 13.66%. The firm's revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.49 earnings per share.
View Globus Medical's earnings history.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical updated its FY 2021 earnings guidance on Thursday, November, 25th. The company provided EPS guidance of $2.000-$2.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.010. The company issued revenue guidance of $950 million-$950 million, compared to the consensus revenue estimate of $952.13 million.

What price target have analysts set for GMED?

11 brokers have issued 12 month target prices for Globus Medical's shares. Their forecasts range from $72.00 to $100.00. On average, they anticipate Globus Medical's share price to reach $87.73 in the next year. This suggests a possible upside of 39.1% from the stock's current price.
View analysts' price targets for Globus Medical or view top-rated stocks among Wall Street analysts.

Who are Globus Medical's key executives?

Globus Medical's management team includes the following people:

• David M. Demski, President, Chief Executive Officer & Director (LinkedIn Profile)
• Keith W. Pfeil, Senior VP, Chief Financial & Accounting Officer (LinkedIn Profile)
• Daniel T. Scavilla, Chief Commercial Officer & Executive VP
• Kelly G. Huller, Secretary, Senior VP & General Counsel
• Brett A. Murphy, Group President-Commercial Operations

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical CEO David Demski on Glassdoor.com. David Demski has an approval rating of 61% among Globus Medical's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Globus Medical's key competitors?

Some companies that are related to Globus Medical include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), DexCom (DXCM), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Masimo (MASI).
View all of GMED's competitors.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Square (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.24%), Janus Henderson Group PLC (5.72%), Wellington Management Group LLP (3.22%), Capital Research Global Investors (1.94%), Kayne Anderson Rudnick Investment Management LLC (1.53%) and AXA S.A. (1.52%). Company insiders that own Globus Medical stock include Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends for Globus Medical.

Which institutional investors are selling Globus Medical stock?

GMED stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Janus Henderson Group PLC, Two Sigma Advisers LP, Capital Research Global Investors, Point72 Asset Management L.P., Eagle Asset Management Inc., Polar Capital Holdings Plc, and SG Americas Securities LLC. Company insiders that have sold Globus Medical company stock in the last year include Daniel T Scavilla, David M Demski, James R Tobin, Keith W Pfeil, and Kelly Huller.
View insider buying and selling activity for Globus Medical or view top insider-selling stocks.

Which institutional investors are buying Globus Medical stock?

GMED stock was bought by a variety of institutional investors in the last quarter, including Marathon Asset Mgmt Ltd, Nordea Investment Management AB, Fuller & Thaler Asset Management Inc., Kayne Anderson Rudnick Investment Management LLC, Invesco Ltd., Geode Capital Management LLC, Arrowstreet Capital Limited Partnership, and Morgan Stanley.
View insider buying and selling activity for Globus Medical or or view top insider-buying stocks.

How do I buy shares of Globus Medical?

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $63.09.

How much money does Globus Medical make?

Globus Medical has a market capitalization of $6.37 billion and generates $789.04 million in revenue each year. The medical device company earns $102.29 million in net income (profit) each year or $1.81 on an earnings per share basis.

How many employees does Globus Medical have?

Globus Medical employs 2,200 workers across the globe.

What is Globus Medical's official website?

The official website for Globus Medical is www.globusmedical.com.

Where are Globus Medical's headquarters?

Globus Medical is headquartered at 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at (610) 930-1800, via email at [email protected], or via fax at 610-930-2042.